Nykode Therapeutics ASA (NYKD) — Cash Flow-to-Debt Ratio
Nykode Therapeutics ASA (NYKD) has a Cash Flow-to-Debt Ratio of -9.25x as of September 2025, meaning its operating cash flow of Nkr-59.64 Million could theoretically repay -9% of its total liabilities (Nkr6.45 Million) in one year. See cash generation quality of Nykode Therapeutics ASA to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nykode Therapeutics ASA Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Nykode Therapeutics ASA across 9 annual periods. Also explore how fast is Nykode Therapeutics ASA growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nykode Therapeutics ASA (2016–2024)
Year-by-year debt coverage analysis for Nykode Therapeutics ASA. For market capitalisation and broader financial context, see Nykode Therapeutics ASA market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.97x | Nkr-51.22 Million | Nkr17.27 Million | ▼ -13.4% |
| 2023 | -2.62x | Nkr-96.62 Million | Nkr36.93 Million | ▼ -715.1% |
| 2022 | -0.32x | Nkr-20.69 Million | Nkr64.46 Million | ▼ -2087.3% |
| 2021 | 0.02x | Nkr1.16 Million | Nkr71.50 Million | ▼ -99.5% |
| 2020 | 3.52x | Nkr180.27 Million | Nkr51.18 Million | ▲ +293.3% |
| 2019 | -1.82x | Nkr-92.08 Million | Nkr50.52 Million | ▲ +61.5% |
| 2018 | -4.73x | Nkr-62.78 Million | Nkr13.27 Million | ▲ +17.6% |
| 2017 | -5.74x | Nkr-62.78 Million | Nkr10.94 Million | ▼ -525.2% |
| 2016 | -0.92x | Nkr-1.60 Million | Nkr1.74 Million | — |